Observational - registry
Heart failure (HF) is a rapidly increasing disease worldwide but there is no global HF study that documents demographics, socioeconomic and clinical factors, diagnostic and management patterns, etiology, biomarkers, co-morbidities, treatments, quality of life, barriers to care and outcomes in all parts of the world. Such knowledge is essential in the prevention and treatment of this global disease.
The primary event outcome of the study will be mortality, by cause. Secondary event outcomes will include non-fatal major events (both resulting in and not resulting in hospitalization).
The G-CHF study will obtain baseline data on participants, from North America, South America, Europe, Africa, Asia and the Middle East, on demographic and socioeconomic data, clinical and laboratory variables, echocardiography, HF etiology, medication use, management patterns, quality of life, barriers to care and health systems. Six-month, 12-month, 18-month and 24-month follow-up data will be obtained to determine changes in management, and patient outcomes.
A sub-study of approximately 4000-5000 patients to measure frailty, cognitive and lung function, mental health, medication adherence, patient-reported barriers to care, dietary assessment, and collection of blood samples for central analysis will additionally be performed.
G-CHF includes risk prediction of heart failure using an integrated genomic-proteomic approach, led by PHRI Senior Scientist, Gui Pare who is also Director of the Genetic and Molecular Epidemiology Laboratory at PHRI/McMaster.Download G-CHF slides March 2021
Observational - registry
Prospective global registry
Executive Director; Senior Scientist
Salim Yusuf is an internationally renowned cardiologist and epidemiologist, whose work over 40 years has substantially influenced prevention and treatment of cardiovascular disease. Born in India, medically qualified at St. John’s Medical College, Bangalore in 1976, he received a Rhodes Scholarship and obtained a DPhil from Oxford, during which he (along with Richard Peto, Rory Collins and Peter Sleight) initiated the concepts of large, simple trials, and meta-analysis. He proposed the concept of combination drug treatment for prevention of CVD to achieve large reductions in CVD with a single pill (now called the polypill concept), but more importantly has been evaluating the concept through large randomized trials.
He leads several global studies involving more than 60 countries in every inhabited continent of the world aimed at enhancing knowledge about the biological, behavioural and societal causes, consequences, and approaches to the control of heart diseases, and strokes through large multi-country programs such as INTERHEART, INTERSTROKE, and PURE.
He holds a Heart and Stroke Foundation of Ontario Research Chair and has received (among others) the Lifetime Research Achievement award of the Canadian Cardiovascular Society; the Paul Wood Silver Medal of the British Cardiac Society; the European Society of Cardiology gold medal, the clinical Research Prize of the American Heart Association and the International Award and the Braunwald Lecture of the American College of Cardiology. He has been inducted into the Royal Society of Canada and the Canadian Medical Hall of Fame; been appointed as an Officer of the Order of Canada, and received the Canada Gairdner Wightman Award in 2014. He has received four honorary doctorates, and is among the top 20 most cited health researchers in history.
Salim Yusuf has published more than 1,000 articles in refereed journals, rising to the second most cited researcher in the world for 2011. He has mentored more than 120 scientists, several of whom are in leadership positions across the globe. He has been President of the World Heart Federation (2015-2016), where he initiated several programs (the Emerging Leaders program, road maps for CVD control and a course for training primary care practitioners in CVD prevention) aimed at halving the CVD burden globally within a generation. The World Heart Federation has recognized his contributions by naming the program the Salim Yusuf Emerging Leaders Programme.
He is a Distinguished University Professor of Medicine, and Executive Director of the Population Health Research Institute, McMaster University and Chief Scientist, Hamilton Health Sciences.
Director, CRLB- GMEL; Senior Scientist
Guillaume Paré is Director of the Clinical Research Laboratory and Biobank (CRLB) – Genetic and Molecular Epidemiology Laboratory (GMEL). He is also Deputy Director of the Thrombosis and Atherosclerosis Research Institute (TaARI), a Professor of Pathology and Molecular Medicine, a Professor in the Department of Health Research Methods, Evidence and Impact, and a University Scholar at McMaster University. He holds the Cisco Professorship in Integrated Health Biosystems.
His clinical interests are centered on lipoprotein disorders, obesity and cardiovascular disease prevention, with research interests in cardiovascular genetics, biomarker development and pharmacogenomics. Gui’s research combines high-throughput biomarker screens with genetics, bioinformatics and epidemiology to identify novel cardio-metabolic biomarkers. He has published more than 200 papers and has been cited over 27,000 times.
A medical biochemist with board certification from the Royal College of Physicians and Surgeons of Canada, Gui completed a Master’s in Human Genetics at McGill University under the supervision of renowned geneticist Thomas Hudson. He further trained in genetic epidemiology with Paul Ridker at Harvard Medical School.
Isabelle Johansson is a Research Fellow at PHRI, supervised by Salim Yusuf, and McMaster University where she is pursuing a Masters in Health Research Methodology, clinical epidemiology. Her main research interests are in heart failure, diabetes, global health, and cardiovascular disease prevention. At PHRI, she is an Investigator in the G-CHF-study and the PURE study. Isabelle was in the 2019 cohort of the World Heart Federation Salim Yusuf Emerging Leaders Programme, focusing on reducing the burden of heart failure globally.
She obtained her M.D. from the Karolinska Institutet Medical University, Stockholm, Sweden in 2014 and has completed two out five years of clinical training in a residency in family medicine. She completed her Ph.D. in medical sciences at the Karolinska Institutet, Department of Medicine in 2017 where she studied epidemiological aspects of heart failure in combination with diabetes. Isabelle was part of the European Society of Cardiology task force writing the guidelines for the management of diabetes and cardiovascular disease presented in September 2019.
Philip Joseph’s research interests include cardiovascular prevention, global health, heart failure, and cardiac imaging. He is the principal investigator for the PURE-AF substudy, and the SPECT-MINS study, an investigator in the PURE study, and the G-CHF registry. He is also the project officer for the TIPS-3 study. He has published more than 30 peer-reviewed scientific papers.
He is a fellow of the Royal College of Physicians and Surgeons of Canada, with certification in both internal medicine and cardiology. obtained his B.A.Sc at McMaster University in 2000, and his M.D. at Western University in 2004. His internal medicine (2004-2007) and cardiology (2007-2010) residencies were completed at the University of Ottawa. Subsequently, he completed additional clinical training in Nuclear Cardiology at McMaster University (2013), a M.Sc. in Health Research Methodology at McMaster (2010-13), and a post-doctoral research fellowship in PET imaging at Harvard University (2015).
Tara McCready, PhD, oversees a variety of collaborative programs at PHRI, and serves as Project Manager for PHRI research studies and registries.
She was recruited to PHRI as a Program Director for the Canadian Network and Centre for Trials Internationally (CANNeCTIN), a national network funded by the CIHR/CFI Clinical Research Initiative program to improve the prevention and treatment of cardiac and vascular diseases and diabetes.
Previously the Executive Director of the Canadian Maternal, Infant, Child and Youth Research Network, Tara holds a PhD in Biochemistry and a MBA in Technology Commercialization from the University of Alberta.
Senior Research Coordinator
Alex Grinvalds has more than 15 years experience in clinical research, of which 13 have been at PHRI. He has worked on randomized studies, device trials and numerous registries. Currently, Alex is working on studies involving patients with heart failure and arrhythmias.
Alex holds a Bachelor of Science degree from Queen’s University and a Certificate in Clinical Research from Humber College.
Back To Top